Suspension of trading
Valuation Acelyrin, Inc.
Stocks
SLRN
US00445A1007
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
16:00:00 2025-05-20 EDT
|
5-day change | 1st Jan Change | ||
| 2.270 USD | +1.79% |
|
-.--% | - |
| 25-05-22 | Acelyrin, Inc.(NasdaqGS:SLRN) dropped from S&P TMI Index | CI |
| 25-05-22 | Acelyrin, Inc.(NasdaqGS:SLRN) dropped from S&P Global BMI Index | CI |
Company Valuation: Acelyrin, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2023 | 2024 |
|---|---|---|
| Market Cap 1 | 726.2 | 315 |
| Change | - | -56.62% |
| Enterprise Value (EV) 1 | 6.241 | -125.6 |
| Change | - | -2,111.88% |
| P/E | -1.37x | -1.26x |
| PBR | 1.11x | 0.69x |
| PEG | 0x | 0x |
| Capitalization / Revenue | - | - |
| EV / Revenue | - | - |
| EV / EBITDA | - | - |
| EV / EBIT | -0.02x | 0.43x |
| EV / FCF | - | - |
| FCF Yield | - | - |
| Dividend per Share 2 | - | - |
| Rate of return | - | - |
| EPS 2 | -5.433 | -2.5 |
| Distribution rate | - | - |
| Net sales | - | - |
| EBITDA | -288.3 | -293 |
| EBIT 1 | -288.4 | -293.5 |
| Net income 1 | -381.6 | -248.2 |
| Net Debt 1 | -719.9 | -440.6 |
| Reference price 2 | 7.460 | 3.140 |
| Nbr of stocks (in thousands) | 97,339 | 100,326 |
| Announcement Date | 3/28/24 | 3/19/25 |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 229M | |
| 20.92x | 7.37x | 14.89x | 1.39% | 70.64B | |
| 37.73x | 9.79x | 30.06x | 0.04% | 66.11B | |
| -16.97x | 7x | -8.8x | -.--% | 27.98B | |
| -76.73x | 14.33x | -69.09x | -.--% | 26.51B | |
| 30.49x | 6.57x | 17.18x | -.--% | 26.44B | |
| 58.84x | 21.89x | 44.4x | 0.26% | 20.4B | |
| 27.41x | 5.14x | 17.24x | -.--% | 20.17B | |
| 1705.69x | 40.09x | 875.29x | -.--% | 15.99B | |
| 17.09x | 5.07x | 11.84x | -.--% | 13.69B | |
| Average | 200.50x | 13.03x | 103.67x | 0.19% | 28.82B | |
| Weighted average by Cap. | 109.52x | 11.04x | 58.45x | 0.37% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SLRN Stock
- Valuation Acelyrin, Inc.
Select your edition
All financial news and data tailored to specific country editions
